SCHEMBL3245015

SCHEMBL3245015

CCOC(=O)CCCCC(NC(=O)/C(C)=C/c1ccc(C(=O)Oc2ccc(C(=N)N)cc2)cc1)C(=O)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 13/20 0.53
F2 P00734 5/20 0.53
KLK1 P06870 4/20 0.53
TMPRSS15 P98073 9/20 0.48
KMT2A Q03164 5/20 0.40
MEN1 O00255 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
HSP90AA1 P07900 1/20 0.40
HPGD P15428 1/20 0.40
SLC22A2 O15244 1/20 0.39
TMPRSS2 O15393 1/20 0.39
F10 P00742 1/20 0.39
PLG P00747 1/20 0.39
F12 P00748 1/20 0.39
PLAU P00749 1/20 0.39
PLAT P00750 1/20 0.39
KLKB1 P03952 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3243407 0.97 PRSS1 (0.54) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL3238801 0.90 PRSS1 (0.53) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL3238646 0.90 PRSS1 (0.53) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL3245090 0.88 PRSS1 (0.51) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL3245001 0.88 PRSS1 (0.57) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL7303523 0.88 PRSS1 (0.57) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL3238704 0.88 PRSS1 (0.56) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL8846583 0.87 PRSS1 (0.49) PRSS1F2KLK1TMPRSS15KMT2A
SCHEMBL3237850 0.86 PRSS1 (0.52) PRSS1F2KLK1TMPRSS15KMT2A
Acetic Acid SCHEMBL8903078 0.86 PRSS1 (0.49) PRSS1F2KLK1TMPRSS15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671057-B2 Therapeutic agent for type II diabetes comprising protease-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2010-03-02 US disclosed
US-20080009537-A1 Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1815865-A1 THERAPEUTIC AGENT FOR DIABETES COMPRISING PROTEASE-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009537-A1 Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound DPP4, IAPP, DPP7 PRSS1 25/4885F2 805/4885KLK1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.